PACIRA BIOSCIENCES, INC. Impairment of Long-Lived Assets Held-for-use
PACIRA BIOSCIENCES, INC. (PCRX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2024-11-06
- PACIRA BIOSCIENCES, INC. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2013 was $0.00.
- PACIRA BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- PACIRA BIOSCIENCES, INC. impairment of long-lived assets held-for-use for fiscal 2011 was $3.02M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | |
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 | |
| 2011-12-31 | $3.02M 10-K · filed 2014-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |